Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
3223536
Reference Type
Journal Article
Title
Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps
Author(s)
Block, M
Year
2015
Is Peer Reviewed?
Yes
Journal
Expert Opinion on Drug Metabolism & Toxicology
ISSN:
1742-5255
EISSN:
1744-7607
Volume
11
Issue
5
Page Numbers
743-756
DOI
10.1517/17425255.2015.1037276
Web of Science Id
WOS:000353918300008
Abstract
Introduction: Modeling and simulation have become important means of answering questions relevant to the development of a drug, making it possible to assess risks early and to reduce costs. Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) models contribute to a comprehensive understanding of the drug, covering specific questions from early discovery through lifecycle management stages. As for other disease areas, in oncology, PBPK and PD models are important topics that remain to be addressed.
Areas covered: This review describes current PBPK and PD approaches, their applicability in drug development in general and specifically in the area of oncology. It discusses the current status and then focuses on key challenges and the potential for future use. It provides cases in which modeling currently cannot answer the questions and assesses the requirements to close gaps for PBPK/PD in oncology.
Expert opinion: PBPK/PD models have led to improvements in identifying risks and reducing costs during the drug development process. Nevertheless, there is a lot of potential, where more rigorous integration of biological knowledge and specific experimental design would result in a more comprehensive biological picture. Ideally, such approaches would reveal the extent to which preclinical work can be extrapolated to clinical settings, thus enabling reliable prediction and, ultimately, reducing failed trials in clinical oncology.
Keywords
mechanistic modeling; oncology; pharmacodynamics; pharmacokinetics; pharmacometrics; physiologically based modeling; systems biology; systems pharmacology
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity